Quintiles, a fully integrated biopharmaceutical services company, has announced the introduction of two new services, Strategic Drug Development and Consulting, to assist biopharmaceutical companies in navigating the complexities of the Asian market, the company has announced.
To help BioPharma companies design and implement drug development strategies that take into account the Asia product commercialization opportunity and regulatory hurdles in advance of the standardized development process, Quintiles' new Strategic Drug Development organization was designated.
Also, to deliver transformational change, the company has launched Consulting at Quintiles practice in Asia to help customers navigate the New Health by linking business strategy, industry expertise and data-driven insights within six practice areas, the company stated in a press release.
“Drug development and commercialization in Asia will benefit greatly from new, strategic approaches,” said Christian Gabel, Ph.D., vice president and head of Consulting at Quintiles Asia. “Quintiles draws on expertise and lessons learned from 30 years of product development and commercialization in the West to bring differentiated approaches to companies in the East. We are introducing new strategic consulting services to the Asia market, such as our Health Technology Assessment that deploys social networking techniques to anticipate shifts in global market access.”
Trying to focus on how to release the latent value locked in Asian assets and markets, this unique amalgamation of strategy and operations across regulatory, clinical and commercial serves an unmet demand for comprehensive guidance.
Recently, the company announced the opening of a business process outsourcing (BPO) and project management center of excellence in Dalian, a major city in northeast China with a multilingual workforce and location ideally suited to serve the Japanese, Chinese and South Korean biopharmaceutical markets.
The Dalian office will provide data management, biostatistics, medical writing, pharmacovigilance, post-marketing safety surveillance and back-office support for administrative functions for global and local biopharma companies
Raju Shanbhag is a contributing editor for HealthTechZone. To read more of Raju’s articles, please visit his columnist page.Edited by
Jennifer Russell
